FranΓ§aisπ See the interactive version (live chart) β
For Aptiv, we replayed every analyst price target of the past 12 months and measured the real outcome: 29% were profitable, average return +4% (218 calls). At 3 months: -0% average return (35% profitable). The higher the %, the more often analysts were right on this stock.
Their past track record on this stock (targets replayed against real prices) β not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| Morgan Stanley | 29 | 38% | +8% |
| Barclays | 21 | 14% | -17% |
| RBC Capital | 17 | 24% | -7% |
| Wells Fargo | 14 | 57% | +11% |
| Oppenheimer | 14 | 21% | -6% |
Is Aptiv overvalued, and is it a good time to buy Aptiv right now? If you're wondering, here's a recap to make up your own mind: Aptiv's valuation vs its sector median, to weigh alongside analyst reliability (above) and past performance. Educational information, not buy advice.
The P/E (price Γ· earnings per share) = how many years of earnings you pay for the stock. The higher it is, the more growth the market expects β but the pricier the stock, so more vulnerable if growth disappoints. The forward P/E uses next year's expected earnings: lower than the current P/E = rising expected earnings. We compare it to the sector median to see whether the stock is expensive relative to its peers.
| Metric | Aptiv | Sector median (Consumer Discretionary) |
|---|---|---|
| P/E | 20.9 | 19.9 |
| Forward P/E | 7.0 | 14.4 |
| Net margin | 1% | 9% |
π Aptiv is valued in line with its sector (20.9 vs 19.9).
π P/E, PEG, marginβ¦: see the glossary
The analyst consensus on Aptiv (APTV) is "Buy" (43 bullish, 0 bearish calls over 12 months). This is not advice: historically, 29% of their targets on this stock turned out profitable over 1 year.
The median 12-month price target is $73.00 (+61% vs $45.44), ranging from $55.00 to $83.00 (12 analysts).
Over 1 year, 29% of analyst targets on Aptiv were profitable, for an average return of +4% (across 218 timestamped calls). This is JPI Invest's accuracy metric.
Analysts target a median of $73.00 within 12 months, i.e. +61% vs the current price. The most bullish targets $83.00, the most cautious $55.00.
Note: analyst targets are 12-month (median $73.00, +61%), NOT 2030. No reliable 5-10 year price forecast exists (Β« 2030 prediction Β» models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (29%), and the stock's past trajectory.
Its P/E is 20.9, forward P/E 7.0. A forward P/E lower than the current P/E means earnings are expected to grow.
π See the full interactive analysis of Aptiv β
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best β on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
Explore JPI Invest for free β How it works: the method β
β οΈ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.